알파선 방출 방사성 리간드 치료 시장 : 동향과 예측(-2035년)

ALPHA-EMITTING RADIOLIGAND THERAPY MARKET: OVERVIEW

As per Roots Analysis, the global alpha-emitting radioligand therapy market is valued at USD 0.75 billion in the current year and is projected to reach USD 3.01 billion by 2035, representing a CAGR of 16.7% during the forecast period.

Alpha-Emitting Radioligand Therapy Market: Growth and Trends

Rising global cancer incidence, particularly advanced prostate cancer, neuroendocrine tumors, and treatment-resistant solid tumors, is accelerating demand for highly potent, short-range targeted therapies. Alpha-emitting radioligands deliver high linear-energy-transfer radiation over a very limited path length, enabling precise tumor-cell kill while sparing surrounding healthy tissue. This positions alpha emitters as a complementary or next-generation modality to established beta-emitting radioligand therapies such as lutetium-177 products.

Key trends include expanding clinical pipelines for actinium-225, lead-212, and radium-223 conjugates; growing investment in isotope production capacity; and increasing integration of theranostic approaches that pair diagnostic imaging with therapeutic alpha delivery. Continuous process intensification, single-use systems, and specialized radiopharmacy infrastructure are moving from emerging concepts to operational necessities as manufacturers seek higher yields and lower per-dose costs. Geopolitical and supply-chain considerations are also prompting onshoring of isotope production and finished-dose manufacturing closer to major end markets.

As targeted alpha therapy becomes an accepted component of precision oncology, the market is positioned for sustained, long-term expansion driven by both commercial products and late-stage pipeline assets.

Growth Drivers: Factors Fueling Market Expansion

Demand is propelled by the clinical need for therapies effective against micrometastases and radio-resistant disease, where alpha particles' high relative biological effectiveness offers clear advantages. Pharmaceutical and biotech companies gain access to specialized isotope production, chelation chemistry, and GMP radiopharmacy capabilities without the full capital burden of in-house nuclear facilities. Operational flexibility allows sponsors to scale manufacturing in line with clinical and commercial demand while redirecting capital toward R&D and indication expansion.

Additional drivers include expanding reimbursement for approved agents, regulatory support for radiopharmaceutical development pathways, rising adoption of PSMA and SSTR-targeted approaches, and the broader shift toward personalized, image-guided oncology.

Market Challenges: Critical Barriers Hindering Progress

Despite strong fundamentals, the market faces constraints, such as limited and geographically concentrated supply of key alpha-emitting isotopes (especially actinium-225), high capital and regulatory requirements for specialized production and handling infrastructure, short half-lives that complicate logistics and scheduling, and the need for trained nuclear-medicine personnel. Stringent radiation-safety and GMP expectations, competition from beta emitters and other modalities such as antibody-drug conjugates, and near-term uncertainty around capacity expansion all add cost and complexity. Addressing isotope supply security, manufacturing scale-up, and cross-disciplinary training will be essential for stakeholders seeking to capture the full opportunity.

Alpha-Emitting Radioligand Therapy Market: Key Insights

The report delves into the current state of the global alpha-emitting radioligand therapy market and identifies potential growth opportunities for distribution partners, channel intermediaries, and specialty logistics providers. Some key findings include:

• Alpha-emitting radioligand therapy developers predominantly rely on direct-to-manufacturer isotope supply agreements and long-term radioisotope offtake contracts, limiting the visibility that conventional pharmaceutical distributors have into this segment despite their established cold-chain and controlled-substance handling networks.
• Specialty radiopharmacy networks and nuclear-medicine-certified logistics providers are emerging as critical enablers of the alpha-therapy supply chain, given the extremely short half-lives (hours to a few days) of isotopes such as astatine-211 and lead-212.
• Distributors and logistics partners seeking entry into this space must demonstrate NRC/IAEA-aligned radioactive materials licensing, validated shielded-transport infrastructure, and GMP-compliant chain-of-custody documentation, reflecting the stringent safety and regulatory requirements attached to alpha-particle-emitting drug products.
• Rapid capacity build-out for actinium-225 and lead-212 production across North America and Europe, led by companies such as NorthStar Medical Radioisotopes, Niowave, Orano Med, and Eckert & Ziegler, is increasing demand for regional distribution and just-in-time logistics partners capable of navigating radioactive materials transport regulations.
• Consolidation among large pharmaceutical sponsors through billion-dollar acquisitions of alpha-therapy biotechs is raising barriers to entry for smaller players, while simultaneously creating openings for niche distributors and logistics providers with isotope-specific or indication-specific expertise.
• Distribution and channel partners increasingly compete on value-added services, including radiation-safety documentation support, temperature- and shielding-controlled transport, dose-calibration coordination, and treatment-center inventory management, rather than on logistics cost alone.
• The expanding late-stage pipeline of PSMA and SSTR2-targeted actinium-225 therapeutics, together with emerging lead-212 and astatine-211 candidates, is expected to sustain elevated demand for specialized isotope distribution infrastructure through the forecast period.

Recent Deal Activity Signaling Investor Momentum

• Niowave and Ratio Therapeutics signed a supply agreement under which Niowave will provide cGMP actinium-225 to support Ratio's clinical-stage targeted radiotherapeutic pipeline.
• NorthStar Medical Radioisotopes and QSA Global entered a multi-year strategic services agreement to secure the radium-226 target supply that underpins NorthStar's commercial-scale, no-carrier-added actinium-225 production.
• ITM Isotope Technologies Munich and Alpha-9 Oncology signed a supply agreement for actinium-225 sourced from Actineer, the ITM-Canadian Nuclear Laboratories joint venture, to support Alpha-9's radiopharmaceutical pipeline.
• AstraZeneca completed its approximately USD 2.4 billion acquisition of Fusion Pharmaceuticals, gaining the actinium-225-based PSMA-targeted asset FPI-2265 and extending a long-term actinium-225 supply agreement with Niowave.
• Bristol Myers Squibb completed its USD 4.1 billion acquisition of RayzeBio, adding an actinium-225-based radiopharmaceutical platform, including the Phase III asset RYZ101, along with in-house manufacturing capability.
• Eli Lilly acquired POINT Biopharma for approximately USD 1.4 billion, adding alpha- and beta-emitting radioligand assets and manufacturing capacity, while Novartis advanced its actinium-225 focus through the acquisition of Mariana Oncology and a licensing arrangement with PeptiDream.

Collectively, these transactions underscore sustained investor and strategic-acquirer confidence in the alpha-emitting radioligand therapy modality, with isotope supply security emerging as the primary strategic asset being acquired, a theme directly relevant to distributors and logistics partners evaluating exposure to this market.

Alpha-Emitting Radioligand Therapy Market Segments

The market sizing and opportunity analysis has been segmented across the following parameters:

By Isotope Type

• Actinium-225 (Ac-225)
• Lead-212 (Pb-212)
• Radium-223 (Ra-223)
• Astatine-211 (At-211)
• Thorium-227 (Th-227)
• Other Alpha-emitting Isotopes

By Product Type

• Marketed Alpha-emitting Radioligand Therapies
• Pipeline / Clinical-stage Candidates

By Targeting Moiety

• Monoclonal Antibodies
• Peptides
• Small Molecules
• Antibody Fragments / Other Constructs

By Indication

• Prostate Cancer (mCRPC)
• Neuroendocrine Tumors (GEP-NETs)
• Bone Metastases
• Hepatocellular Carcinoma
• Hematological Malignancies (AML)
• Other Solid Tumors

By End User

• Hospitals and Specialized Cancer Centers
• Nuclear Medicine / Theranostic Centers
• Ambulatory Infusion and Outpatient Treatment Centers

By Distribution Channel

• Direct-to-Center Manufacturer Distribution
• Third-Party Radiopharmacy Networks
• Specialty Cold-Chain / Radioactive Logistics Distributors

By Geographical Regions

• North America
• US
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Rest of Asia-Pacific
• Middle East and North Africa
• Saudi Arabia
• UAE
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Alpha-Emitting Radioligand Therapy Market: Key Segments

Actinium-225 Leads the Isotope-Type Landscape

Based on Roots Analysis research, actinium-225-based candidates account for the highest share of the active alpha-emitting radioligand therapy market. This leading position reflects Ac-225's favorable four-alpha-particle decay chain, established radiolabeling chemistry, and its adoption as the lead isotope across the RayzeBio, Fusion Pharmaceuticals, and Novartis actinium programs. Lead-212 is expected to register the fastest CAGR through 2035 as accelerator-based generator systems mature and reduce dependence on the constrained actinium-225 supply chain.

Prostate Cancer Remains the Dominant Indication

According to our analysis, mCRPC accounts for the largest indication-wise share of the alpha-emitting radioligand therapy pipeline. This highest share is underpinned by the large post-Pluvicto patient pool and multiple PSMA-targeted actinium-225 candidates in late-stage development. Neuroendocrine tumors represent the second-largest segment, led by RYZ101, and are projected to grow at a robust CAGR as sponsors pursue post-Lutathera treatment settings.

North America Dominates the Market and Asia-Pacific Registers a High CAGR

North America currently accounts for the largest share of global alpha-emitting radioligand therapy market. This high share is supported by the concentration of isotope production capacity, the presence of leading sponsors (Bristol Myers Squibb, AstraZeneca, Eli Lilly, Novartis), a mature theranostics infrastructure, and favorable reimbursement pathways. Europe follows, aided by isotope production hubs in Germany and the ITM-Canadian Nuclear Laboratories partnership, while Asia-Pacific is expected to post the fastest regional CAGR as China, Japan, and South Korea expand nuclear medicine capacity and cyclotron-based isotope production.

Nuclear Medicine and Theranostic Centers Lead by End User

Specialized nuclear medicine and theranostic centers currently administer the majority of alpha-emitting radioligand doses, given the radiation-safety infrastructure, dosimetry expertise, and PET-based patient selection capabilities required. Community hospital and ambulatory infusion settings are expected to expand their share as isotope supply stabilizes and simplified administration protocols are established.

Example Players In The Alpha-Emitting Radioligand Therapy Market

• AstraZeneca (Fusion Pharmaceuticals)
• Actinium Pharmaceuticals
• Bristol Myers Squibb (RayzeBio)
• Bayer
• Convergent Therapeutics
• Eli Lilly (POINT Biopharma)
• ITM Isotope Technologies Munich
• Novartis
• NorthStar Medical Radioisotopes
• Orano Med
• Perspective Therapeutics
• Telix Pharmaceuticals

ALPHA-EMITTING RADIOLIGAND THERAPY MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: An in-depth analysis of the market focusing on key segments, including isotope type, product type, targeting moiety, indication, end user, distribution channel, and geographical regions.
• Isotope Supply Chain Landscape: A detailed assessment of active and emerging actinium-225, lead-212, and other alpha-isotope producers, featuring production route, capacity, and supply-agreement information.
• Company Profiles: In-depth profiles of prominent players engaged in alpha-emitting radioligand therapy development and isotope production, covering pipeline assets, manufacturing capabilities, and recent initiatives.
• Case Study (Alpha versus Beta Emitters): A concise comparison of alpha- and beta-emitting radioligand therapies, highlighting decay characteristics, manufacturing complexity, and clinical trade-offs.
• Partnerships and Collaborations: An analysis of isotope supply agreements, licensing deals, and manufacturing collaborations, based on parameters such as year of partnership, type of agreement, and most active players.
• Funding and M&A Analysis: A detailed analysis of funding rounds and acquisitions in this domain, based on year, deal value, purpose, geography, and most active acquirers and investors.
• Capacity and Demand Analysis: A comprehensive assessment of global installed isotope production capacity and projected clinical demand across major geographic regions.
• SWOT Analysis: A strategic assessment evaluating the market's key strengths, weaknesses, opportunities, and threats, with actionable insights into competitive positioning.

KEY QUESTIONS ANSWERED IN THIS REPORT

• Which are the leading companies in the alpha-emitting radioligand therapy market?
• Which isotope type and indication dominate the current pipeline, and which are growing fastest?
• What is the current and projected market size, and what is the CAGR through 2035?
• What are the key drivers, trends, and challenges shaping this market?
• How is the actinium-225 and lead-212 supply chain structured, and where are the bottlenecks?
• What opportunities exist for distributors, radiopharmacies, and logistics partners entering this space?
• Which region dominates the market, and which region is projected to grow fastest?
• How is market opportunity distributed across isotope type, indication, end user, and distribution channel?

REASONS TO BUY THIS REPORT

This report is designed to give distributors, channel partners, and investors a decisive analytical edge in a fast-consolidating, supply-constrained market. Its core differentiators include:

• Top-Down and Bottom-Up Triangulated Forecasting: Market estimates are built using a hybrid methodology that cross-validates macro-level assessments against bottom-up, program-level clinical and capacity data, minimizing forecast bias.
• Isotope-Specific Segmentation: Granular segmentation by isotope type (Ac-225, Pb-212, Ra-223, At-211, Th-227) enables precise opportunity sizing tied to production capacity and supply-agreement activity.
• Primary Research-Backed Insights: Findings are informed by direct engagement with executives across isotope producers, radiopharmaceutical sponsors, and logistics providers, ensuring insights reflect real operating conditions.
• Actionable Multi-Parameter Segmentation: Seven-parameter segmentation (isotope type, product type, targeting moiety, indication, end user, distribution channel, geography) enables precise opportunity sizing for any go-to-market or investment thesis.

ADDITIONAL BENEFITS

• Complementary PPT Insights Pack
• Complementary Excel Data Packs for All Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated Report if the Current Edition Is 6-12 Months Old or Older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Market Share Insights
• 1.3. Key Market Insights
• 1.4. Report Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
  • 2.2.1. Market Landscape and Market Trends
  • 2.2.2. Market Forecast and Opportunity Analysis
  • 2.2.3. Comparative Analysis
• 2.3. Database Building
  • 2.3.1. Data Collection
  • 2.3.2. Data Validation
  • 2.3.3. Data Analysis
• 2.4. Project Methodology
  • 2.4.1. Secondary Research
    • 2.4.1.1. Annual Reports
    • 2.4.1.2. Academic Research Papers
    • 2.4.1.3. Company Websites
    • 2.4.1.4. Investor Presentations
    • 2.4.1.5. Regulatory Filings
    • 2.4.1.6. White Papers
    • 2.4.1.7. Industry Publications
    • 2.4.1.8. Conferences and Seminars
    • 2.4.1.9. Government Portals
    • 2.4.1.10. Media and Press Releases
    • 2.4.1.11. Newsletters
    • 2.4.1.12. Industry Databases
    • 2.4.1.13. Roots Proprietary Databases
    • 2.4.1.14. Paid Databases and Sources
    • 2.4.1.15. Social Media Portals
    • 2.4.1.16. Other Secondary Sources
  • 2.4.2. Primary Research
    • 2.4.2.1. Types of Primary Research
      • 2.4.2.1.1. Qualitative Research
      • 2.4.2.1.2. Quantitative Research
      • 2.4.2.1.3. Hybrid Approach
    • 2.4.2.2. Advantages of Primary Research
    • 2.4.2.3. Techniques for Primary Research
      • 2.4.2.3.1. Interviews
      • 2.4.2.3.2. Surveys
      • 2.4.2.3.3. Focus Groups
      • 2.4.2.3.4. Observational Research
      • 2.4.2.3.5. Social Media Interactions
    • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
      • 2.4.2.4.1. Company Executives (CXOs)
      • 2.4.2.4.2. Board of Directors
      • 2.4.2.4.3. Company Presidents and Vice Presidents
      • 2.4.2.4.4. Research and Development Heads
      • 2.4.2.4.5. Technical Experts
      • 2.4.2.4.6. Subject Matter Experts
      • 2.4.2.4.7. Scientists
      • 2.4.2.4.8. Doctors and Other Healthcare Providers
    • 2.4.2.5. Ethics and Integrity
      • 2.4.2.5.1. Research Ethics
      • 2.4.2.5.2. Data Integrity
  • 2.4.3. Analytical Tools and Databases
• 2.5. Robust Quality Control

3. MARKET DYNAMICS

• 3.1. Chapter Overview
• 3.2. Forecast Methodology
  • 3.2.1. Top-down Approach
  • 3.2.2. Bottom-up Approach
  • 3.2.3. Hybrid Approach
• 3.3. Market Assessment Framework
  • 3.3.1. Total Addressable Market (TAM)
  • 3.3.2. Serviceable Addressable Market (SAM)
  • 3.3.3. Serviceable Obtainable Market (SOM)
  • 3.3.4. Currently Acquired Market (CAM)
• 3.4. Forecasting Tools and Techniques
  • 3.4.1. Qualitative Forecasting
  • 3.4.2. Correlation
  • 3.4.3. Regression
  • 3.4.4. Extrapolation
  • 3.4.5. Convergence
  • 3.4.6. Sensitivity Analysis
  • 3.4.7. Scenario Planning
  • 3.4.8. Data Visualization
  • 3.4.9. Time Series Analysis
  • 3.4.10. Forecast Error Analysis
• 3.5. Key Considerations
  • 3.5.1. Demographics
  • 3.5.2. Government Regulations
  • 3.5.3. Reimbursement Scenarios
  • 3.5.4. Market Access
  • 3.5.5. Supply Chain
  • 3.5.6. Industry Consolidation
  • 3.5.7. Pandemic / Unforeseen Disruptions Impact
• 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

• 4.1. Chapter Overview
• 4.2. Market Dynamics
  • 4.2.1. Time Period
    • 4.2.1.1. Historical Trends
    • 4.2.1.2. Current and Forecasted Estimates
  • 4.2.2. Currency Coverage
    • 4.2.2.1. Major Currencies Affecting the Market
    • 4.2.2.2. Factors Affecting Currency Fluctuations
    • 4.2.2.3. Impact of Currency Fluctuations on the Industry
  • 4.2.3. Foreign Currency Exchange Rate
    • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
    • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 4.2.4. Recession
    • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
  • 4.2.5. Inflation
    • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
  • 4.2.6. Interest Rates
    • 4.2.6.1. Interest Rates and Their Impact on the Market
    • 4.2.6.2. Strategies for Managing Interest Rate Risk
  • 4.2.7. Commodity Flow Analysis
    • 4.2.7.1. Type of Commodity
    • 4.2.7.2. Origins and Destinations
    • 4.2.7.3. Values and Weights
    • 4.2.7.4. Modes of Transportation
  • 4.2.8. Global Trade Dynamics
    • 4.2.8.1. Import Scenario
    • 4.2.8.2. Export Scenario
    • 4.2.8.3. Trade Policies
    • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
    • 4.2.8.5. Impact of Trade Barriers on the Market
  • 4.2.9. War Impact Analysis
    • 4.2.9.1. Russian-Ukraine War
    • 4.2.9.2. Israel-Hamas War
  • 4.2.10. COVID Impact / Related Factors
    • 4.2.10.1. Global Economic Impact
    • 4.2.10.2. Industry-specific Impact
    • 4.2.10.3. Government Response and Stimulus Measures
    • 4.2.10.4. Future Outlook and Adaptation Strategies
  • 4.2.11. Other Indicators
    • 4.2.11.1. Fiscal Policy
    • 4.2.11.2. Consumer Spending
    • 4.2.11.3. Gross Domestic Product (GDP)
    • 4.2.11.4. Employment
    • 4.2.11.5. Taxes
    • 4.2.11.6. Stock Market Performance
    • 4.2.11.7. Cross-Border Dynamics
• 4.3. Conclusion

5. EXECUTIVE SUMMARY

6. INTRODUCTION

• 6.1. Chapter Overview
• 6.2. Overview of T-cell Immunotherapies
  • 6.2.1. Historical Evolution
  • 6.2.2. Key Considerations for Alpha-Emitting Radioligand Therapy
  • 6.2.3. Strategies Employed for the Redirection of Alpha-Emitting Radioligand Therapy
  • 6.2.4. Manufacturing of Alpha-Emitting Radioligand Therapies
• 6.3. Concluding Remarks

7. ALPHA-EMITTING RADIOLIGAND THERAPY: MARKET LANDSCAPE

• 7.1. Chapter Overview
• 7.2. Alpha-Emitting Radioligand Therapy: Market Landscape
  • 7.2.1. Analysis by Type of Isotope
  • 7.2.2. Analysis by Type of Product
  • 7.2.3. Analysis by Target Moiety
  • 7.2.4. Analysis by Indication
  • 7.2.5. Analysis by End User
  • 7.2.6. Analysis by Distribution Channel
• 7.3. Alpha-Emitting Radioligand Therapy: Overall Developer Landscape
  • 7.3.1. Analysis by Year of Establishment
  • 7.3.2. Analysis by Company Size
  • 7.3.3. Analysis by Location of Headquarters

8. CLINICAL TRIAL ANALYSIS

• 8.1. Chapter Overview
• 8.2. Scope and Methodology
• 8.3. Alpha-Emitting Radioligand Therapy: Clinical Trial Analysis
  • 8.3.1. Analysis by Trial Registration Year
  • 8.3.2. Analysis of Enrolled Patient Population by Trial Registration Year
  • 8.3.3. Analysis by Trial Phase
  • 8.3.4. Analysis of Enrolled Patient Population by Trial Phase
  • 8.3.5. Analysis by Trial Registration Year and Trial Phase
  • 8.3.6. Analysis by Trial Status
  • 8.3.7. Analysis by Patient Gender
  • 8.3.8. Analysis by Therapeutic Area
  • 8.3.9. Analysis by Study Design
  • 8.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
  • 8.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
  • 8.3.12. Analysis by Geography

9. COMPANY PROFILES

• 9.1. Chapter Overview
• 9.2. AstraZeneca (Fusion Pharmaceuticals)
• 9.3. Actinium Pharmaceuticals
• 9.4. Bristol Myers Squibb Company (RayzeBio)
• 9.5. Bayer
• 9.6. Convergent Therapeutics
• 9.7. Eli Lilly (POINT Biopharma)
• 9.8. ITM Isotope Technologies Munich
• 9.9. Novartis
• 9.10. NorthStar Medical Radioisotopes
• 9.11. Orano Med
• 9.12. Perspective Therapeutics
• 9.13. Telix Pharmaceuticals

10. PARTNERSHIPS AND COLLABORATIONS

• 10.1. Chapter Overview
• 10.2. Partnership Models
• 10.3. Alpha-Emitting Radioligand Therapy: Partnerships and Collaborations
  • 10.3.1. Analysis by Year of Partnership
  • 10.3.2. Analysis by Type of Partnership
  • 10.3.3. Analysis by Year and Type of Partnership
  • 10.3.4. Analysis by Type of Partner
  • 10.3.5. Most Popular Therapies: Analysis by Number of Partnerships
  • 10.3.6. Most Active Industry Players: Analysis by Number of Partnerships
  • 10.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
  • 10.3.8. Analysis by Geography
    • 10.3.8.1. Intercontinental and Intracontinental Agreements
    • 10.3.8.2. International and Local Agreements

11. FUNDING AND INVESTMENTS ANALYSIS

• 11.1. Chapter Overview
• 11.2. Types of Funding
• 11.3. Alpha-Emitting Radioligand Therapy: Funding and Investment Analysis
  • 11.3.1. Analysis by Year of Funding
  • 11.3.2. Analysis of Amount Invested
  • 11.3.3. Analysis by Type of Funding
  • 11.3.4. Analysis by Amount Invested and Type of Funding
  • 11.3.5. Analysis of Amount Invested by Year and Type of Funding
  • 11.3.6. Analysis by Type of Investor
  • 11.3.7. Analysis by Geography
  • 11.3.8. Most Active Players
  • 11.3.9. Leading Investors: Analysis by Number of Funding Instances

12. PATENT ANALYSIS

• 12.1. Chapter Overview
• 12.2. Scope and Methodology
• 12.3. Alpha-Emitting Radioligand Therapy: Patent Analysis
  • 12.3.1. Analysis by Patent Publication Year
  • 12.3.2. Analysis by Patent Application Year
  • 12.3.3. Analysis of Granted Patents and Patent Applications by Publication Year
  • 12.3.4. Analysis by Patent Jurisdiction
  • 12.3.5. Analysis by CPC Symbols
  • 12.3.6. Analysis by Type of Applicant
  • 12.3.7. Leading Industry Players: Analysis by Number of Patents
  • 12.3.8. Leading Non-Industry Players: Analysis by Number of Patents
  • 12.3.9. Leading Patent Assignees: Analysis by Number of Patents
• 12.4. Patent Benchmarking Analysis
  • 12.4.1. Analysis by Patent Characteristics
• 12.5. Patent Valuation
• 12.6. Leading Patents by Number of Citations

13. CASE STUDY: CELL THERAPY MANUFACTURING

• 13.1. Chapter Overview
• 13.2. Overview of Cell Therapy Manufacturing
• 13.3. Cell Therapy Manufacturing Models
  • 13.3.1. Centralized Manufacturing Model
  • 13.3.2. Decentralized Manufacturing Model
• 13.4. Scalability of Cell Therapy Manufacturing Processes
  • 13.4.1. Scale-Up
  • 13.4.2. Scale-Out
• 13.5. Types of Cell Therapy Manufacturers
• 13.6. Key Challenges Related to Manufacturing of Cell Therapies
• 13.7. Key Considerations for Cell Therapy Manufacturing
  • 13.7.1. Characterization
  • 13.7.2. Cost of Goods
• 13.8. Automation of Cell Therapy Manufacturing Process
• 13.9. Cell Therapy Manufacturing Supply Chain
• 13.10. Comparison of Players Having In-house Capabilities and Contract Manufacturers
• 13.11. Regulatory Landscape
• 13.12. Future Perspectives

14. COST PRICE ANALYSIS

• 14.1. Chapter Overview
• 14.2. Factors Contributing to the High Price of Cell / Gene Therapies
• 14.3. Pricing Models for T-cell Immunotherapies
  • 14.3.1. Based on Associated Costs
  • 14.3.2. Based on Availability of Competing Products
  • 14.3.3. Based on Patient Population
  • 14.3.4. Based on Opinions of Industry Experts
• 14.4. Reimbursement related Considerations for T-cell Immunotherapies
  • 14.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapies

15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

• 15.1. Chapter Overview
• 15.2. Market Drivers
• 15.3. Market Restraints
• 15.4. Market Opportunities
• 15.5. Market Challenges
• 15.6. Conclusion

16. GLOBAL ALPHA-EMITTING RADIOLIGAND THERAPY MARKET

• 16.1. Chapter Overview
• 16.2. Key Assumptions and Methodology
• 16.3. Global Alpha-Emitting Radioligand Therapy Market, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
• 16.4. Scenario Analysis
  • 16.4.1. Conservative Scenario
  • 16.4.2. Optimistic Scenario
• 16.5. Key Market Segmentations

17. ALPHA-EMITTING RADIOLIGAND THERAPY MARKET, BY ISOTOPE TYPE

• 17.1. Chapter Overview
• 17.2. Key Assumptions and Methodology
• 17.3. Alpha-Emitting Radioligand Therapy Market: Distribution by Isotope
  • 17.3.1. Alpha-Emitting Radioligand Therapy Market for Actinium-225 (Ac-225): Forecasted Estimates (till 2035)
    • 17.3.1.1. Alpha-Emitting Radioligand Therapy Market for Lead-212 (Pb-212): Forecasted Estimates (till 2035)
    • 17.3.1.2. Alpha-Emitting Radioligand Therapy Market for Radium-223 (Ra-223): Forecasted Estimates (till 2035)
    • 17.3.1.3. Alpha-Emitting Radioligand Therapy Market for Astatine-211 (At-211): Forecasted Estimates (till 2035)
    • 17.3.1.4. Alpha-Emitting Radioligand Therapy Market for Thorium-227 (Th-227): Forecasted Estimates (till 2035)
    • 17.3.1.5. Alpha-Emitting Radioligand Therapy Market for Other Alpha-Emitting Isotopes: Forecasted Estimates (till 2035)
• 17.4. Data Triangulation and Validation

18. ALPHA-EMITTING RADIOLIGAND THERAPY MARKET, BY PRODUCT TYPE

• 18.1. Chapter Overview
• 18.2. Key Assumptions and Methodology
• 18.3. Alpha-Emitting Radioligand Therapy Market: Distribution by Product Type
  • 18.3.1. Alpha-Emitting Radioligand Therapy Market for Marketed Alpha-Emitting Radioligand Therapies: Forecasted Estimates (till 2035)
  • 18.3.2. Alpha-Emitting Radioligand Therapy Market for Pipeline / Clinical-Stage Candidates: Forecasted Estimates (till 2035)
• 18.4. Data Triangulation and Validation

19. ALPHA-EMITTING RADIOLIGAND THERAPY MARKET, BY TARGET MOIETY

• 19.1. Chapter Overview
• 19.2. Key Assumptions and Methodology
• 19.3. Alpha-Emitting Radioligand Therapy Market: Distribution by Target Moiety
  • 19.3.1. Alpha-Emitting Radioligand Therapy Market for Monoclonal Antibodies: Forecasted Estimates (till 2035)
  • 19.3.2. Alpha-Emitting Radioligand Therapy Market for Peptides: Forecasted Estimates (till 2035)
  • 19.3.2. Alpha-Emitting Radioligand Therapy Market for Small Molecules: Forecasted Estimates (till 2035)
  • 19.3.2. Alpha-Emitting Radioligand Therapy Market for Antibody Fragments / Other Constructs: Forecasted Estimates (till 2035)
• 19.4. Data Triangulation and Validation

20. ALPHA-EMITTING RADIOLIGAND THERAPY MARKET, BY INDICATION

• 20.1. Chapter Overview
• 20.2. Key Assumptions and Methodology
• 20.3. Alpha-Emitting Radioligand Therapy Market: Distribution by Indication
  • 20.3.1. Alpha-Emitting Radioligand Therapy Market for Prostate Cancer (mCRPC): Forecasted Estimates (till 2035)
  • 20.3.2. Alpha-Emitting Radioligand Therapy Market for Neuroendocrine Tumors (GEP-NETs): Forecasted Estimates (till 2035)
  • 20.3.3. Alpha-Emitting Radioligand Therapy Market for Bone Metastases: Forecasted Estimates (till 2035)
  • 20.3.4. Alpha-Emitting Radioligand Therapy Market for Hepatocellular Carcinoma: Forecasted Estimates (till 2035)
  • 20.3.5. Alpha-Emitting Radioligand Therapy Market for Hematological Malignancies (AML): Forecasted Estimates (till 2035)
  • 20.3.6. Alpha-Emitting Radioligand Therapy Market for Other Solid Tumors: Forecasted Estimates (till 2035)
• 20.4. Data Triangulation and Validation

21. ALPHA-EMITTING RADIOLIGAND THERAPY MARKET, BY END USER

• 21.1. Chapter Overview
• 21.2. Key Assumptions and Methodology
• 21.3. Alpha-Emitting Radioligand Therapy Market: Distribution by End User
  • 21.3.1. Alpha-Emitting Radioligand Therapy Market for Hospitals and Specialized Cancer Centers: Forecasted Estimates (till 2035)
  • 21.3.2. Alpha-Emitting Radioligand Therapy Market for Nuclear Medicine / Theranostic Centers: Forecasted Estimates (till 2035)
  • 21.3.3. Alpha-Emitting Radioligand Therapy Market for Ambulatory Infusion and Outpatient Treatment Centers: Forecasted Estimates (till 2035)
• 21.4. Data Triangulation and Validation

22. ALPHA-EMITTING RADIOLIGAND THERAPY MARKET, BY DISTRIBUTION CHANNEL

• 22.1. Chapter Overview
• 22.2. Key Assumptions and Methodology
• 22.3. Alpha-Emitting Radioligand Therapy Market: Distribution by Distribution Channel
  • 22.3.1. Alpha-Emitting Radioligand Therapy Market for Direct-to-Center Manufacturer Distribution: Forecasted Estimates (till 2035)
  • 22.3.2. Alpha-Emitting Radioligand Therapy Market for Third-Party Radiopharmacy Networks: Forecasted Estimates (till 2035)
  • 22.3.3. Alpha-Emitting Radioligand Therapy Market for Specialty Cold-Chain / Radioactive Logistics Distributors: Forecasted Estimates (till 2035)
• 22.4. Data Triangulation and Validation1

23. ALPHA-EMITTING RADIOLIGAND THERAPY MARKET: DISTRIBUTION BY GEOGRAPHICAL REGIONS

• 23.1. Chapter Overview
• 23.2. Key Assumptions and Methodology
• 23.3. Alpha-Emitting Radioligand Therapy Market: Distribution by Key Geographical Regions
  • 23.3.1. Alpha-Emitting Radioligand Therapy Market in North America: Forecasted Estimates (till 2035)
  • 23.3.2. Alpha-Emitting Radioligand Therapy Market in Europe: Forecasted Estimates (till 2035)
  • 23.3.3. Alpha-Emitting Radioligand Therapy Market in Asia-Pacific: Forecasted Estimates (till 2035)
  • 23.3.4. Alpha-Emitting Radioligand Therapy Market in Latin America: Forecasted Estimates (till 2035)
  • 23.3.5. Alpha-Emitting Radioligand Therapy Market in Middle East and North Africa: Forecasted Estimates (till 2035)
  • 23.3.6. Alpha-Emitting Radioligand Therapy Market in Rest of the World: Forecasted Estimates (till 2035)
• 23.4. Data Triangulation and Validation

24. ALPHA-EMITTING RADIOLIGAND THERAPY MARKET, SALES FORECAST OF DRUGS

• 24.1. Chapter Overview
• 24.2. Key Assumptions and Methodology
• 24.3. Commercialized Alpha-Emitting Radioligand Therapy: Sales Forecast
• 24.4. Clinical Alpha-Emitting Radioligand Therapy: Sales Forecast
• 24.5. Data Triangulation and Validation

25. ALPHA-EMITTING RADIOLIGAND THERAPY MARKET: SALES FORECAST OF LEADING PLAYERS

• 25.1. Chapter Overview
• 25.2. Key Assumptions and Methodology
• 25.3. Alpha-Emitting Radioligand Therapy: Leading Players
• 25.4. Data Triangulation and Validation

26. EXECUTIVE INSIGHTS

27. CONCLUDING REMARKS

28. APPENDIX I: TABULATED DATA

29. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

30. APPENDIX III: LIST OF FUNDING AND INVESTMENTS